Wolf-Hagen Schunck

Wolf is biochemist at the Max Delbrück Center for Molecular Medicine. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Wolf’s laboratory identified 17,18-EEQ laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Wolf is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

John R. Falck

John is the Welch Distinguished Chair of Chemistry and Professor at the University of Texas Southwestern Medical Center and has over 40 years of research experience in the field of medicinal and synthetic chemistry. He has pioneered the identification, preparation and chemical synthesis of a number of epoxyeicosatrienoic acids and is one of the foremost experts in the application of chemistry and pharmacology of CYP eicosanoids.

Dominik N. Müller

Dominik is pharmacist and group leader at the Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine. He has over 25 years of research experience in the field. His current work is focused on the crosstalk between immune cells, vasculature and target organs of hypertension. His research group’s major research interests are beside the understanding of pathomechanisms leading to cardiovascular disease, the identification of cardiovascular risk factors and new target for treatment.

Robert Fischer

Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led or participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.

Karen Uhlmann

Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin.